Company intelligence / Profile preview
Vaxine
Adelaide, South Australia, Australiavaxine.net ↗
- Ownership
- Private
- Employees
- ~35
- Development stage
- Commercial
01
Overview
Vaxine has developed several vaccine candidates using its proprietary Advax™ adjuvant technology. Its COVID‑19 vaccine candidate has advanced through clinical trials and demonstrated safety and immunogenicity. The company also develops influenza and other infectious disease vaccines.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Protein subunit vaccinesVirus-like particle (VLP) vaccinesAdjuvanted vaccines
- Industry
- Biotech
02
Drug pipeline
24 assets23 more assets in the full pipeline.
03
Partnerships
Collaborations with Flinders University, South Australia Health & Medical Research Institute, and international research groups for clinical development.Partnerships with government agencies during the COVID pandemic for rapid vaccine development support.
Beyond the preview
Go deeper on Vaxine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxine.